Global Short Bowel Syndrome (SBS) Market 2017-2021
About Short Bowel Syndrome (SBS)
Short bowel syndrome (SBS) is a metabolic disorder occurs when the portion of the small intestine is not functioning or removed through surgery due to digestive illness. SBS is caused by lack of function of the small intestine. This results in malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition. Based on drug class, the market is segmented into GLP-2, growth hormone, glutamine, and others.
Technavio’s analysts forecast the global short bowel syndrome (SBS) market to grow at a CAGR of 25.53% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global short bowel syndrome (SBS) market for 2017-2021. To calculate the market size, the report considers the sales of the drugs and related nutraceutical products.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Short Bowel Syndrome (SBS) Market 2017-2021
Technavio recognizes the following companies as the key players in the global short bowel syndrome (SBS) market: Emmaus Medical, Merck, and Shire.
Other Prominent Vendors in the market are: Ardelyx, Naia Pharmaceuticals, Nutrinia, OxThera, Sancilio Pharmaceuticals, and Zealand Pharma.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is increased awareness of GI disorders. Pharmaceutical companies and national and local government bodies such as the health ministry and municipalities are conducting programs to spread awareness of GI disorders. Many NGOs also conduct camps to educate people and raise the awareness level. Drug manufacturers supply visual aids or free samples to physicians and sometimes to individuals to spread awareness of the disorders and promote their drugs. This is done to increase the knowledge of the individuals about a particular GI disorder.”
According to the report, one of the major drivers for this market is special drug designations. As the market is dominated by a few drugs and the pipeline also demonstrates the same, the special designation will provide more opportunity for revenue generation and to expand geographically. These designations carry benefits such as an extension of patent exclusivity period to address the need for an orphan drug, tax credits of up to 50% of R&D costs, and orphan drug’s sponsors are exempted from paying the US FDA application fees. These benefits will reduce the burden from vendors to develop a product for a rare disease.
Further, the report states that one of the major factors hindering the growth of this market is severe side effects of the drugs. The side effects involved in the use of GATTEX may hinder the adoption rates. GATTEX is a GLP-2 analog used for the treatment of adult patients with SBS who are dependent on parenteral support. There is an increased risk that abnormal cells could become cancer. The few other side effects associated with GATTEX is swelling (inflammation) or blockage in gallbladder or pancreas or fluid overload. These side effects could lead to trouble in having a bowel movement or passing gas, stomach area (abdomen) pain or swelling, nausea, vomiting, swelling, and blockage in stoma opening.
Emmaus Medical, Merck, Shire, Ardelyx, Naia Pharmaceuticals, Nutrinia, OxThera, Sancilio Pharmaceuticals, and Zealand Pharma.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook